Samsung Biologics is showing strong performance. It is believed to be influenced by the news that it has signed a pharmaceutical contract manufacturing agreement worth 1.4637 trillion KRW with a US-based pharmaceutical company.
As of 2 PM on the 2nd, Samsung Biologics is trading at 786,000 KRW, up 3.56% compared to the previous day.
On the 2nd, Samsung Biologics announced that it had signed a CMO contract worth 1.06 billion USD (approximately 1.4637 trillion KRW) with a US pharmaceutical company, marking the largest contract in its history. This order exceeds 40% of Samsung Biologics' total order amount of 3.5009 trillion KRW last year.
This contract is the main agreement following the letter of intent (LOI) signed in June last year, finalized after about a year with an increase of 1.3164 trillion KRW compared to the LOI. The client and product names are not disclosed due to confidentiality clauses, and the contract period lasts until December 31, 2030.
Meanwhile, through this contract, Samsung Biologics has surpassed a cumulative annual order amount of 2.5 trillion KRW in just six months.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
